Three gene sequencing studies from Penn Medicine show patterns that may help detect problems earlier and potentially better treat acute myeloid leukemia (AML). The findings were presented recently at the annual meeting of the American Society of Hematology (ASH), where thousands of researchers and physicians gathered from around the world to hear the latest findings on blood disorders and cancers. In three separate studies, physicians from the Abramson Cancer Center and researchers from Penn’s Center for Personalized Diagnostics looked at three groups of patients: younger ones, those with secondary AML and those with a skin condition known as leukemia cutis, using next generation sequencing to find answers in their genetic makeup.
Read the Department of Communications post.